Lexicon Pharmaceuticals

US · LXRX #3430 by market cap

1.76 +0.01 +0.57%

Live - 5344 symbols - heartbeat 244s ago · 2026-10-08 08:59

Pre-market 1.74 -0.90%

After-hours 1.76 0.00%

Overnight 1.78 +1.14%

Market cap: 783.12M
P/E (TTM): -11.00
P/B: 4.49
EPS: -0.14
Div yield: 0.00%
52W pos: 42%

Reader sentiment Are you bullish or bearish on LXRX?

Anonymous reader poll. Unscientific, not investment advice.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Founded: 1995
CEO: Dr. Michael Exton, PhD
Employees: 81
Headquarters: The Woodlands, Texas, United States of America
Fiscal year end: 12-31
Website: lexpharma.com

Company profile

Exchange: US
Symbol: LXRX
Market-cap rank: #3430
Market cap: 783.12M
Float cap: 385.42M
Shares out: 444.96M
Float shares: 218.99M

Sectors & themes

Biotechnology Global medical industry

Browse all sectors & themes

Quote time 2026-10-08 08:59:29 · For reference only, not investment advice and not tailored to your situation.